Carboprost tromethamine is a synthetic form of the hormone prostaglandin F2α, which has been used in medical practice for over four decades now. It is commonly used to induce labor, control postpartum hemorrhage and terminate pregnancy, among other uses. This article will discuss carboprost tromethamine in detail, with an emphasis on the various uses and dosages for medical professionals. In addition, it will provide information on safety concerns and potential side effects that healthcare professionals should be aware of when administering this medication to their patients.
Carboprost tromethamine is a synthetic prostaglandin analogue used to induce labor and control postpartum hemorrhage. It is sold under the brand names Hemabate and Methergine. Carboprost tromethamine has a similar structure to natural prostaglandins, which are hormones that play an important role in regulating many bodily functions, including labor and delivery. When given as an injection, carboprost tromethamine works by stimulating contractions of the uterus and increasing the production of oxytocin, a hormone that helps control bleeding after childbirth. Carboprost tromethamine is typically only used when other methods of induction or control of postpartum hemorrhage have failed.
Carboprost tromethamine is indicated for the medical termination of pregnancy through 63 days gestational age. It can also be used to control postpartum hemorrhage when uterine contractions are inadequate. Common side effects of carboprost tromethamine include nausea, vomiting, diarrhea, abdominal pain and fever.
Carboprost tromethamine (Hemabate) is a prostaglandin F2-alpha analogue used to treat postpartum hemorrhage (PPH) due to uterine atony. It is administered as an intramuscular injection. The recommended dose of carboprost tromethamine for the treatment of PPH is 0.25 mg/kg administered intramuscularly every 15 minutes for two doses, followed by 0.5 mg/kg every 30 minutes for four doses, and then 1 mg/kg every 60 minutes as needed. The maximum recommended dose is 30 mg per day. For the prevention of PPH, the recommended dose of carboprost tromethamine is 0.5 mg/kg administered intramuscularly immediately after delivery of the placenta.
Carboprost tromethamine is a medication used to help induce labor or to control bleeding after childbirth or abortion. It is a synthetic version of the hormone prostaglandin F2α. Carboprost tromethamine should only be used under the supervision of a medical professional. Carboprost tromethamine should only be used under the supervision of a medical professional. It is not intended for use by pregnant women without medical supervision. This medication can cause uterine contractions. This medication can also cause side effects such as nausea, vomiting, diarrhea, abdominal pain and headache.
Carboprost tromethamine (Hemabate) is a synthetic prostaglandin used to induce labor or terminate pregnancy. It can also be used to control postpartum bleeding. Carboprost tromethamine works by causing the uterus to contract. Common side effects of carboprost tromethamine include nausea, vomiting, diarrhea, headache and dizziness. This medication may also cause uterine rupture and other serious side effects in pregnant women.
Drug interactions may occur with carboprost tromethamine. The most common drug interactions include: Nonsteroidal anti-inflammatory drugs (NSAIDs), Anticoagulants (blood thinners), Aspirin, Barbiturates, Corticosteroids, Diuretics (water pills), estrogens, lithium
Carboprost Tromethamine is an important medication used to treat several medical conditions. As a medical professional, it is essential that you understand the uses, dosages and other aspects of using this drug correctly. We hope this article has provided all of the necessary information for safely administering Carboprost Tromethamine so that you can ensure your patients are receiving the best care possible.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Men over 75 years old may be significantly more likely to commit suicide if they have cancer.
2.
Screening tests that are non-invasive show promise in detecting colorectal cancer.
3.
Eight Doctors Killed in Brazil's Horrifying Plane Crash
4.
Doctors say lung cancer is still the deadliest cancer, but hope is growing
5.
MRI-guided radiation therapy improves quality of life with fewer side effects in patients with localized cancer. JAMA
1.
Tailoring the Immune Response: The Dawn of Personalized Vaccines in Cancer Immunotherapy
2.
Exploring New Treatment Options for Hemophilia: A Journey into the Unknown
3.
Practical Applications in Hematology Across Clinical Settings
4.
A New Hope: Exploring Treatment Options for Waldenstrom's Macroglobulinemia
5.
Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers
1.
International Conference on Oncology, Cardiology and Critical Care Policy
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Cancer Nursing and Hematology Support
1.
Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Important Points to Know
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation